Evaluation of efficacy and safety of feline interleukin-2 immunomodulator following surgical excision of feline fibrosarcoma


Feline sarcoma is an aggressive tumor that has a high rate of return, despite surgical removal of this cancer.

In this study researchers will test whether a feline interleukin-2 immunomodulator injections (intended to stimulate the immune system) will decrease the rate of cancer recurrence compared to the current standard of care which is surgical removal by itself.


To be eligible for this study, cats must meet several criteria, including but not limited to the following:

  • Clinically confirmed diagnosis of feline fibrosarcoma (TNM stage T1N0M0) less than 5cm in diameter that is amenable to surgical resection
  • Tumor cannot be present on the head, tail, or distal limbs
  • Must be FeLV, FIV negative

For more information about this study and to inquire about eligibility and potential study benefits, please contact Nicole Leibman, DVM, DACVIM (Oncology) 212-329-8696 or 212-329-8740 (nicole.leibman@amcny.org).

Back to top